Since the start of the SARS-CoV-2 pandemic, several variants of the virus have developed into Variants of Concern (VOCs), as classified by the World Health Organization (WHO). VOCs are virus variants
TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich in collaboration with the German Center for Infection Research (DZIF), has entered its